Intercept Pharma Q2 EPS $(0.14) Beats $(0.56) Estimate, Sales $83.72M Beat $78.72M Estimate
Portfolio Pulse from Benzinga Newsdesk
Intercept Pharma (NASDAQ:ICPT) reported Q2 earnings per share of $(0.14), beating the analyst consensus estimate of $(0.56) by 75%. The company also reported quarterly sales of $83.72 million, surpassing the analyst consensus estimate of $78.72 million by 6.35%. Both figures represent an increase from the same period last year.
August 04, 2023 | 10:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intercept Pharma's Q2 earnings and sales beat analyst estimates, which could lead to a positive market reaction.
Intercept Pharma's better-than-expected Q2 earnings and sales figures are likely to be viewed positively by the market. This could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100